Influence of renal dysfunction on efficiency of treatment by glivec in patients with chronic myeloleukemia
Abstract
The aim of the work was to study correlation between the treatment efficiency of CML patients with glivec and the initial kidneys filtration rate. 62 patients with chronic or accelerating phase of CML receiving glivec were examined. The efficiency was assessed by achievement of remission and by gaining of cytogenetic reaction. A majority (56%) of patients with glomerular filtration rate (GFR) below 60 ml/min had high risk of CML progress. Patients with initial GFR <60 ml/min had no hematologic reaction to a 6 month long treatment significantly more frequently than those with GFR ³90 ml/min. Complete cytogenetic reaction (CGR) was achieved after 12 months of glivec therapy in 89% patients with initial GFR ³90 ml/min. CGR was not achieved in 92% of patients with initial GFR <60 ml/min. The initial GFR correlates with the risk level of disease progressing on glivec treatment. Glivec toxicity also correlates with the initial GFR.
About the Authors
O. M. Senderova
ГУЗ «Иркутская областная клиническая больница»
Russian Federation
Russian Federation
G. M. Orlova
Иркутский государственный медицинский университет; г. Иркутск
Russian Federation
Russian Federation
References
1. Воробьев А.И. Руководство по гематологии. М.: Ньюдиамед, 2003.
2. Зарицкий А.Ю., Ломайя Э.Г., Виноградова О.Ю., Туркина А.Г. и др. Результаты многоцентрового исследования терапии гливеком больных хроническим миелолейкозом в хронической фазе. Гематология и трансфузиология, 2007. № 2. С. 13-17.
3. Земченков А.Ю. «К/ДОКИ» обращается к истокам хронической почечной недостаточности. А.Ю. Земченков, Н.А. Томилина. Нефрология и диализ 2004. № 3. С. 204-220.
4. Туркина А.Г., Виноградова О.Ю., Хорошко. Н.Д., Воробьев А.И. Российский регистр больных хроническим миелолейкозом. Гематология и трансфузиология, 2007. № 2. С. 7-11.
5. Туркина А.Г., Хорошко Н.Д. Практические рекомендации по лечению больных хроническим миелолейкозом: пособие для врачей. М., 2005. С. 12-13.
6. Deininger M.N. Chronic myeloid leukemia. Management of early stage disease. J Hematology Am Soc Hematol, 2005. Р. 174-182.
7. Drucer B.J., Lydon N.B. Lessons learned from the development of an abl tyrosin kinase inhibitor for chronic myeloid leukemia. J Clin Invest, 2000. Vol. 105. Р. 3-7.
8. Guilhot F.G., Roy L., Millot F. Update of first-line in chronic phase myeloid leukemia. Hematology, education program of the 11 congress of EHA, Amsterdam, the Netherlands, June 15-18, 2006. Р. 93-97.
9. Kantarjian H.M., Cortes J.E., O’Brien S. et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia. High incidence of early complete and major cytogenetic responses. Blood, 2003. Vol. 101. Р. 97-100.
Review
For citations:
Senderova O.M., Orlova G.M. Influence of renal dysfunction on efficiency of treatment by glivec in patients with chronic myeloleukemia. Nephrology and Dialysis. 2009;11(1):35-38. (In Russ.)
Views:
5
Email this article 